{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:14:11Z","timestamp":1782281651452,"version":"3.54.5"},"reference-count":13,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Infectious Diseases Institute in Kampala"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"Merck and ViiV Healthcare"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jac\/dky379","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T11:26:19Z","timestamp":1535714779000},"source":"Crossref","is-referenced-by-count":7,"title":["High efavirenz serum concentrations in TB\/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment"],"prefix":"10.1093","author":[{"given":"Amrei","family":"von Braun","sequence":"first","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"},{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Castelnuovo","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Ledergerber","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Cusato","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Buzibye","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kambugu","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fehr","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland"},{"name":"Department of Public Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2534-8815","authenticated-orcid":false,"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Lamorde","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Sekaggya-Wiltshire","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"key":"key\n\t\t\t\t20180918110231_dky379-B1","volume-title":"Global Tuberculosis Report 2017","author":"WHO","year":"2017"},{"key":"key\n\t\t\t\t20180918110231_dky379-B2","volume-title":"Treatment of Tuberculosis: Guidelines","author":"WHO","year":"2010"},{"key":"key\n\t\t\t\t20180918110231_dky379-B3","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/jac\/dkv183","article-title":"Efavirenz and the CNS: what we already know and questions that need to be answered","volume":"70","author":"Apostolova","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180918110231_dky379-B4","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Guti\u00e9rrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180918110231_dky379-B5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180918110231_dky379-B6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2125.2005.02536.x","article-title":"Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism","volume":"61","author":"Burger","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180918110231_dky379-B7","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1093\/jac\/dku286","article-title":"Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4\u03b2-hydroxycholesterol during efavirenz treatment and efavirenz\/rifampicin co-treatment","volume":"69","author":"Ngaimisi","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180918110231_dky379-B8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/135965350901400502","article-title":"The effect of rifampicin-based antitubercular therapy and cytochrome P450 2B6 genotype on efavirenz mid-dosing interval concentrations in a South African HIV-infected population","volume":"14","author":"Cohen","year":"2009","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180918110231_dky379-B9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiu429","article-title":"Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection","volume":"211","author":"Dooley","year":"2015","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180918110231_dky379-B10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"ENCORE1 Study Group","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180918110231_dky379-B11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2217\/pgs.16.7","article-title":"CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population","volume":"17","author":"Mukonzo","year":"2016","journal-title":"Pharmacogenomics"},{"key":"key\n\t\t\t\t20180918110231_dky379-B12","doi-asserted-by":"crossref","first-page":"e014679.","DOI":"10.1136\/bmjopen-2016-014679","article-title":"Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study","volume":"7","author":"Sekaggya-Wiltshire","year":"2017","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180918110231_dky379-B13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/cid\/ciy179","article-title":"Delayed sputum culture conversion in tuberculosis\u2013human immunodeficiency virus-coinfected patients with low isoniazid and rifampicin concentrations","volume":"67","author":"Sekaggya-Wiltshire","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dky379\/25795304\/dky379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T01:08:41Z","timestamp":1661908121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dky379\/5101396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":13,"URL":"https:\/\/doi.org\/10.1093\/jac\/dky379","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,18]]}}}